SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

Escalating US-Iran tensions, marked by military strikes and oil supply concerns, are driving intense SPY discussion as the community debates a potential market downturn against resilient "buy the dip" narratives amidst geopolitical uncertainty.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is a top trending stock as escalating Middle East tensions, driven by reported attacks on oil infrastructure and disruption in the Strait of Hormuz, ignite community speculation of a massive price surge and potential short squeeze for this low-float oil play, drawing comparisons to past energy rallies.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

BATL is trending as escalating Middle East tensions trigger a surge in oil prices, with the community actively discussing its significant short interest and the potential for a massive short squeeze as a primary driver.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid heightened US-Iran conflict, triggering debates over a potential market 'bloodbath' driven by rising oil prices and geopolitical instability. However, many in the community contend that the 'war is priced in,' anticipating another 'V recovery' as dip buyers and algorithmic trading systems demonstrate surprising resilience for tech stocks.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Heightened geopolitical tensions impacting global LNG supply routes, coupled with strong anticipation for its upcoming earnings, are driving significant conversation around Venture Global. The community is actively discussing the company's rapid production expansion, perceived undervaluation relative to peers, and the potential for a substantial short squeeze.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is seeing a dramatic surge driven by a strong earnings beat and highly ambitious revenue guidance for its AI-focused 800G/1.6T data center transceivers. The community is intensely debating whether this marks a legitimate re-rating and short squeeze due to massive industry demand, or if it's an overhyped run susceptible to an announced stock offering and the company's past execution challenges.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas is a focal point for investors amid escalating global tensions, as its autonomous drone and counter-UAS technologies are seen as increasingly vital, sparking community speculation about significant contract wins and a potential short squeeze on its substantial short interest.

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

USO is trending due to escalating geopolitical tensions in the Middle East following reported US-Israeli strikes on Iran and subsequent regional retaliation, raising significant concerns about global oil supply disruptions, particularly within the critical Strait of Hormuz. The community is actively discussing a potential surge in crude prices, with many anticipating oil could reach $100 or higher amid fears of a prolonged conflict and a short squeeze in the energy sector.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is surging amid heightened geopolitical tensions in the Middle East, with reports of attacks on Saudi oil infrastructure and fears over the closure of the Strait of Hormuz fueling speculation of drastically higher crude prices and a "war trade" for energy stocks.

BP Plc operates as an integrated oil and gas company providing carbon products and services. It operates through the following segments: Gas and Low Carbon Energy, Oil Production and Operations, and Customers and Products. The Gas and Low Carbon Energy segment includes upstream businesses focused on natural gas production, gas marketing and trading activities, as well as solar, wind, and hydrogen ventures. The Oil Production and Operations segment comprises regions with upstream activities that predominantly produce crude oil. The Customers and Products segment includes customer-focused businesses, including convenience and retail fuels, EV charging, Castrol, aviation, B2B, and midstream, along with refining, oil trading, and bioenergy businesses. The company was founded by William Knox D'Arcy in 1908 and is headquartered in London, the United Kingdom.

BP plc - ADR

Heightened geopolitical tensions in the Middle East are fueling community speculation around BP's oil price upside, while its recent significant oil discovery, strong Q2 earnings, and a major LNG arbitration win are also driving robust discussion.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Silo Pharma's stock buzz increased on Wednesday after the company reported crucial development steps for SPC-15, their main product which serves as an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD).&nbsp;Silo entered into a partnership with Frontage Laboratories to perform a 7-day significant animal safety and toxicology study as requested by the FDA.&nbsp;Shares of the company closed at $0.84 on Wednesday, down 23.3% for the day, and declined further by 4.9% to $0.80 in after-hours trading.Silo is moving forward with an IND-enabling Good Laboratory Practice (GLP)-compliant toxicology and toxicokinetic study focused on SPC-15.Completing the toxicology studies with favorable outcomes will enable the submission of an IND application in 2025.&nbsp;Silo intends to start a first-in-human Phase 1 clinical trial for SPC-15 after receiving approval.&nbsp;The pharma company has obtained an exclusive worldwide license from Columbia University to develop SPC-15 further and enable its manufacturing and commercial distribution.Additionally, Silo also partnered with Veloxity Labs to provide bioanalysis services for its current GLP toxicology and toxicokinetics research.&nbsp;The company confirmed its plan to start the FDA IND process for SPC-15 in 2025, with the goal of advancing to clinical trials once approval is obtained.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 3,300% surge in 24-hour message volume.One user mentioned that buying shares under a dollar has been consistently profitable for them over the past five years, though they plan to exit within three to six months, adding that catching pre-market price spikes requires early mornings.&nbsp;<stembedurl>https://stocktwits.com/Helson/message/614607172</stembedurl>Another user noted they took a 9% gain on the stock and planned to exit soon.<stembedurl>https://stocktwits.com/Bdport/message/614597364</stembedurl>The stock has declined 12% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Silo Pharma Retail Buzz Surges On FDA Toxicology Study Plans For PTSD Treatment

The company announced FDA-requested toxicology studies for its PTSD treatment SPC-15, fueling optimism for a 2025 IND submission and Phase 1 trial.

Equity

After a Patent Win, Analysts Think This Penny Stock Can Gain 465% in 2025

Amid the dynamic biopharma landscape, this penny stock is turning heads with a game-changing patent win, and analysts are buzzing with bullish projections for its potential.

Silo Pharma (SILO) isn't your typical market mover. But on Tuesday, this small-cap biopharma stock defied expectations, skyrocketing over 123% to become the undisputed champion of U.S. gainers. The secret weapon? An exclusive global license agreement for a promising Alzheimer's drug.Wednesday's pre-market trading painted a different picture as the stock fell by as much as 13%, suggesting some investors are taking profits after the wild ride. However, at around 11 am ET, shares had rebounded, gaining over 2%.<figure class="image"><img style="aspect-ratio:1322/756;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SILO_stock_move_Jul_17_c1ed653683.png" alt="SILO stock move Jul 17" width="1322" height="756"><figcaption>SILO stock move Jul 17</figcaption></figure>But hold on, the story doesn't end there. SILO is still capturing retail investor attention like never before. Stocktwits data reveals a surge in interest: the stock has the most new watchers in the past 24 hours, and follower counts have skyrocketed by a whopping 453% over the past week.The excitement stems from a licensing deal for SPC-14, an Alzheimer's drug currently in preclinical development. Silo Pharma plans to leverage the FDA's streamlined pathway, potentially speeding up clinical trials and reducing costs.&nbsp;With the global Alzheimer's treatment market expected to reach a staggering $30.8 billion by 2033, the potential is undeniable.Retail investors on Stocktwits are buzzing, bullish about the deal's potential to supercharge SILO's value. This comes on the heels of a similar licensing agreement for their lead drug candidate targeting stress and PTSD.&nbsp;With shares already up 57% year-to-date and hitting 11-month highs, the latest development could still trigger a retail frenzy for SILO over the longer-term, despite the pre-market dip.Representative <a href="https://pixabay.com/illustrations/neurons-brain-cells-brain-structure-7420662/">image</a> by Gerd Altmann from Pixabay

Why This Small-Cap Biopharma Is Getting The Most Retail Attention On Stocktwits Today

Silo Pharma’s shares more than doubled yesterday, driven by a promising new Alzheimer’s drug agreement.

Silo Pharma’s shares more than doubled yesterday as retail investors flock to the stock, driven by a promising new Alzheimer’s drug agreement.

This account has been verified as an official SILO representative.

Verified Account

Silo Pharma

Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. It seeks to acquire and develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs. The company was founded by Eric Weisblum on July 13, 2010 and is headquartered in Sarasota, FL.

SILO Pharma Inc

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

SILO
SILO Pharma Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest SILO News

SILOSILO Pharma Inc